RECOVER-TLC opens expanded enrollment in REVERSE-LC clinical trial

As part of the next phase of RECOVER clinical trials, RECOVER-Treating Long COVID (RECOVER-TLC) is creating new opportunities to participate in Long COVID research. Four new studies will invite people with Long COVID to join clinical trials testing the safety and effectiveness of possible treatments for their symptoms.

The first of these studies to begin enrollment is the REVERSE-LC study. In this clinical trial, researchers will test whether the drug baricitinib can improve brain function, heart and lung function, and quality of life for adults with Long COVID. 

Baricitinib is an FDA-approved treatment for rheumatoid arthritis and COVID-19. It belongs to a class of drugs known as JAK/STAT inhibitors. These drugs work by helping to prevent and reduce inflammation. Inflammation is part of immune system’s normal response to infection, but an over-active immune response can lead to chronic (long-lasting) inflammation that can have negative health impacts. 

Scientists believe that some Long COVID symptoms, like brain fog and fatigue, may be caused by inflammation. Members of the Long COVID community have also identified JAK/STAT inhibitors as drugs worthy of further study. To date, RECOVER-TLC has received 12 unique submissions for treatment ideas using JAK/STAT inhibitors through its online portal.

RECOVER-TLC has expanded the ongoing REVERSE-LC study to add 11 new trial sites, bringing the total to 17 sites nationwide. Seven of these study sites are actively screening individuals with Long COVID to see if they are eligible to participate. With the addition of these new sites, REVERSE-LC has also increased its enrollment goal to 550 participants.

Learn more about REVERSE-LC by visiting the study's website. Additional details, including a study overview and contacts, information about who is eligible to join, and how researchers will conduct the study, are available in the study record published on the ClinicalTrials.gov website.